About 9 results found for searched term "X-Gal" (0.053 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M7495 | X-Gal | Others |
| BCIG | ||
| X-Gal is a used in cloning procedures with IPTG. | ||
| M25607 | ARV-766 | PROTAC |
| Luxdegalutamide | ||
| ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. ARV-766 has the potential to be first- and best-in class PROTAC AR degrader in mCRPC. | ||
| M9448 | X-α-Gal | Others |
| X-alpha-Gal | ||
| X-α-Gal is suitable as a substrate for α-galactosidase. | ||
| M16366 | 6-Dehydroxy-8-hydroxygaleopsinolone | Diterpenoids |
| 6-Dehydroxy-8-hydroxygaleopsinolone | ||
| M16577 | 6-Methoxykaempferol 3-O-galactoside | Flavonoids |
| 6-Methoxykaempferol 3-O-galactoside | ||
| M17037 | 3,4,5-Trimethoxyphenyl- (6'-O-galloyl)-O-β-D-glucopyranoside | Phenols |
| 3,4,5-Trimethoxyphenyl- (6'-O-galloyl)-O-β-D-glucopyranoside | ||
| M21396 | Lucerastat | Glucosylceramide Synthase |
| NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin | ||
| Lucerasta is the galactose form of Miglustat, an orally active inhibitor of glucosylceramide synthase (GCS).Lucerastat has potential for use in Fabry disease research. | ||
| M30575 | Migalastat hydrochloride | Others |
| DGJ; 1-Deoxygalactonojirimycin; GR181413A | ||
| Migalastat hydrochloride (DGJ; 1-Deoxygalactonojirimycin; GR181413A) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A. | ||
| M55372 | Ketodeoxynonulosonic acid | Others |
| KDN; 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid | ||
| Ketodeoxynonulosonic acid (KDN; 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid) is a sialic acid, it protects the oligo/(poly)sialyl chains from exosialidases at nonreducing terminal, and plays a role in egg activation of salmonid fish. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
